Yahoo · Sep 11, 2026
LCUT or HLN: Which Is the Better Value Stock Right Now?
LCUT vs. HLN: Which Stock Is the Better Value Option?
HL
NYSE · HLN
Haleon plc
Healthcare · Drug Manufacturers - Specialty & Generic
$9.24
Down-$0.15 (-1.60%)
Updated Sep 16, 2026, 7:08 AM
SID Score
5.5/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 43.5B
- P/E ratio
- 21.41
- Dividend yield
- 1.90%
- 52-week range
- $8.65 – $11.28
- Volume
- 15.42M
- Avg. volume
- 11.03M
Price performance
HLN price history
1M range · 20 trading sessions · Daily adjusted prices
HLN closed at $9.24 after 20 trading sessions, down 4.94% for the selected period.
- Last close
- $9.24
- Period change
- -4.94%
- Period low
- $9.19
- Period high
- $10.18
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $9.24 | $9.32 | $9.19 | $9.24 | 15.42M |
| Sep 14, 2026 | $9.41 | $9.44 | $9.32 | $9.39 | 13.82M |
| Sep 11, 2026 | $9.20 | $9.22 | $9.10 | $9.19 | 10.04M |
| Sep 10, 2026 | $9.21 | $9.265 | $9.17 | $9.22 | 16.74M |
| Sep 9, 2026 | $9.20 | $9.26 | $9.13 | $9.23 | 18.99M |
| Sep 8, 2026 | $9.35 | $9.36 | $9.185 | $9.25 | 16.77M |
| Sep 4, 2026 | $9.61 | $9.735 | $9.57 | $9.60 | 18.17M |
| Sep 3, 2026 | $9.895 | $9.90 | $9.675 | $9.86 | 16.8M |
| Sep 2, 2026 | $9.95 | $10.025 | $9.91 | $9.91 | 10.53M |
| Sep 1, 2026 | $10.15 | $10.20 | $10.05 | $10.07 | 11.24M |
| Aug 31, 2026 | $10.06 | $10.129 | $10.0155 | $10.03 | 8.4M |
| Aug 28, 2026 | $10.04 | $10.11 | $10.03 | $10.11 | 7.91M |
| Aug 27, 2026 | $10.03 | $10.115 | $9.995 | $10.04 | 10.24M |
| Aug 26, 2026 | $10.25 | $10.26 | $10.16 | $10.17 | 5.4M |
| Aug 25, 2026 | $10.09 | $10.195 | $10.045 | $10.18 | 5.58M |
| Aug 24, 2026 | $9.98 | $10.205 | $9.97 | $10.16 | 13.66M |
| Aug 21, 2026 | $9.91 | $10.03 | $9.895 | $10.00 | 8.12M |
| Aug 20, 2026 | $9.82 | $9.93 | $9.795 | $9.87 | 8.08M |
| Aug 19, 2026 | $9.81 | $9.96 | $9.79 | $9.87 | 11.62M |
| Aug 18, 2026 | $9.65 | $9.805 | $9.63 | $9.72 | 9.48M |
Latest HLN news
The latest Smart Investors Daily articles mentioning HLN.
Stock researchCompany · Overview
HLN research
Overview
Company profile and research snapshot.
Company profile
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $10.20
- Implied upside
- —
- Analysts
- 5
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 1, 2026 | Deutsche | Sell | — |
| Jun 25, 2026 | JP Morgan Cazenove | Underweight | — |
| May 5, 2026 | Jefferies | Buy | — |
| Apr 30, 2026 | Berenberg Bank | Buy | — |
| Apr 30, 2026 | RBC Capital Markets | Sector Perform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 5, 2026
Haleon And 2 British AI Healthcare Stocks To Watch
With UK gilt yields responding to shifting Bank of England expectations, investors are rethinking where dependable long term growth could come from. Healthcare companies using artificial intelligence to improve diagnosis and treatment sit at the crossroads of technology and essential services, which can matter when borrowing costs and inflation concerns move in and out of focus. This article highlights three UK listed AI healthcare stocks from our screener to put on your radar. The stocks...
Benzinga · Sep 4, 2026
Sensodyne Maker Haleon Leverages Eye-Level Shelf Placement To Outpace Rivals-Report
Haleon gains US market share at Walmart and Target by securing eye-level shelf placement with aggressive promotional strategies.
Benzinga · Sep 3, 2026
'Haleon Says It Negotiated Better Walmart, Target Shelf Space Via U.S. Price Deals; Haleon Says Improved Shelf Positions Are Driving U.S. Market Share' - Reuters Exclusive
Haleon offers lower prices, promotions, new products and exclusivity to secure improved shelf positionsNielsenIQ data shows Haleon's U.S. consumer health market share has grown every month since FebruaryBernstein
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
